• Bristol Myers Squibb reported iza-bren outperformed chemotherapy in the Phase 3 PANKU-Breast01 breast cancer trial, reducing disease progression or death.
• The trial enrolled patients with advanced HR-positive, HER2-negative breast cancer whose disease had progressed despite prior chemotherapy.
• Safety was manageable, with no new safety signals identified; few patients discontinued treatment because of treatment-related adverse events.
• Results will be presented at ESMO 2026, running October 23-27 in Madrid, with simultaneous publication in The Lancet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202610230730BIZWIRE_USPR_____20261022_BW086856) on October 23, 2026, and is solely responsible for the information contained therein.